Profile data is unavailable for this security.
About the company
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.
- Revenue in GBP (TTM)0.00
- Net income in GBP-436.95k
- Incorporated2015
- Employees2.00
- LocationNuformix PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 12 2362 7222
- Websitehttps://nuformix.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Ovoca Bio PLC | 0.00 | -2.00m |
| Voyager Life PLC | 314.00k | -1.10m |
| Nuformix PLC | 0.00 | -436.95k |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m |
| ReNeuron Group Plc | 249.00k | -5.07m |
| N4 Pharma PLC | 1.95k | -1.28m |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn |
| ValiRx Plc | 9.60k | -2.04m |
| TheraCryf PLC | 838.00k | -3.35m |
| Fusion Antibodies PLC | 1.58m | -2.84m |
| IXICO PLC | 6.67m | -1.18m |
| BSF Enterprise PLC | 12.94k | -1.50m |
